Literature DB >> 21321193

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Norio Chihara1, Toshimasa Aranami, Wakiro Sato, Yusei Miyazaki, Sachiko Miyake, Tomoko Okamoto, Masafumi Ogawa, Tatsushi Toda, Takashi Yamamura.   

Abstract

Neuromyelitis optica (NMO) is an inflammatory disease affecting the optic nerve and spinal cord, in which autoantibodies against aquaporin 4 (AQP4) water channel protein probably play a pathogenic role. Here we show that a B-cell subpopulation, exhibiting the CD19(int)CD27(high)CD38(high)CD180(-) phenotype, is selectively increased in the peripheral blood of NMO patients and that anti-AQP4 antibodies (AQP4-Abs) are mainly produced by these cells in the blood of these patients. These B cells showed the morphological as well as the phenotypical characteristics of plasmablasts (PB) and were further expanded during NMO relapse. We also demonstrate that interleukin 6 (IL-6), shown to be increased in NMO, enhanced the survival of PB as well as their AQP4-Ab secretion, whereas the blockade of IL-6 receptor (IL-6R) signaling by anti-IL-6R antibody reduced the survival of PB in vitro. These results indicate that the IL-6-dependent B-cell subpopulation is involved in the pathogenesis of NMO, thereby providing a therapeutic strategy for targeting IL-6R signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321193      PMCID: PMC3048150          DOI: 10.1073/pnas.1017385108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

2.  Treatment of neuromyelitis optica: current debate.

Authors:  Tomoko Okamoto; Masafumi Ogawa; Youwei Lin; Miho Murata; Sachiko Miyake; Takashi Yamamura
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

Authors:  Rachel Ettinger; Gary P Sims; Anna-Marie Fairhurst; Rachel Robbins; Yong Sing da Silva; Rosanne Spolski; Warren J Leonard; Peter E Lipsky
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

4.  Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.

Authors:  Senad Divanovic; Aurelien Trompette; Sowsan F Atabani; Rajat Madan; Douglas T Golenbock; Alberto Visintin; Robert W Finberg; Alexander Tarakhovsky; Stefanie N Vogel; Yasmine Belkaid; Evelyn A Kurt-Jones; Christopher L Karp
Journal:  Nat Immunol       Date:  2005-04-24       Impact factor: 25.606

5.  Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus.

Authors:  Sajjad Nasir; Douglas A Kerr; Julius Birnbaum
Journal:  Arch Neurol       Date:  2009-09

6.  Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.

Authors:  Shannon R Hinson; Andrew McKeon; James P Fryer; Metha Apiwattanakul; Vanda A Lennon; Sean J Pittock
Journal:  Arch Neurol       Date:  2009-09

Review 7.  Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.

Authors:  Sven Jarius; Friedemann Paul; Diego Franciotta; Patrick Waters; Frauke Zipp; Reinhard Hohlfeld; Angela Vincent; Brigitte Wildemann
Journal:  Nat Clin Pract Neurol       Date:  2008-03-11

8.  Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).

Authors:  M Capobianco; S Malucchi; A di Sapio; F Gilli; A Sala; R Bottero; F Marnetto; C Doriguzzi Bozzo; A Bertolotto
Journal:  Neurol Sci       Date:  2007-08-10       Impact factor: 3.307

9.  Neuromyelitis optica: Passive transfer to rats by human immunoglobulin.

Authors:  Makoto Kinoshita; Yuji Nakatsuji; Takashi Kimura; Masayuki Moriya; Kazushiro Takata; Tatsusada Okuno; Atsushi Kumanogoh; Koji Kajiyama; Hiroo Yoshikawa; Saburo Sakoda
Journal:  Biochem Biophys Res Commun       Date:  2009-06-21       Impact factor: 3.575

10.  APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.

Authors:  Elodie Belnoue; Maria Pihlgren; Tracy L McGaha; Chantal Tougne; Anne-Françoise Rochat; Claudia Bossen; Pascal Schneider; Bertrand Huard; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

View more
  119 in total

Review 1.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

Review 2.  New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review).

Authors:  Qinfang Xie; Mengjiao Sun; Jing Sun; Ting Zheng; Manxia Wang
Journal:  Exp Ther Med       Date:  2020-12-16       Impact factor: 2.447

Review 3.  Current understanding of the epidemiologic and clinical characteristics of optic neuritis.

Authors:  Masanori Nakazawa; Hitoshi Ishikawa; Taiji Sakamoto
Journal:  Jpn J Ophthalmol       Date:  2021-05-22       Impact factor: 2.447

Review 4.  Monoclonal antibodies in treatment of multiple sclerosis.

Authors:  P S Rommer; A Dudesek; O Stüve; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 5.  Neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

Review 6.  Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.

Authors:  M J Hofer; I L Campbell
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

7.  Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.

Authors:  Susanna Brauner; Ann Eriksson-Dufva; Max Albert Hietala; Thomas Frisell; Rayomand Press; Fredrik Piehl
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

Review 8.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

9.  Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors.

Authors:  Mary E Hamby; Giovanni Coppola; Yan Ao; Daniel H Geschwind; Baljit S Khakh; Michael V Sofroniew
Journal:  J Neurosci       Date:  2012-10-17       Impact factor: 6.167

Review 10.  CD19 as a molecular target in CNS autoimmunity.

Authors:  Olaf Stüve; Clemens Warnke; Krystin Deason; Martin Stangel; Bernd C Kieseier; Hans-Peter Hartung; Hans-Christian von Büdingen; Diego Centonze; Thomas G Forsthuber; Volker Knappertz
Journal:  Acta Neuropathol       Date:  2014-07-04       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.